Unknown

Dataset Information

0

Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).


ABSTRACT: AIMS:To compare the once-daily rivastigmine patch 9.5 mg/24 h (10 cm(2) ) versus twice-daily capsule (12 mg/day) in Chinese patients with probable Alzheimer's disease (AD) (mini-mental state examination [MMSE] scores of 10-20). METHODS:The primary objective was to demonstrate the noninferiority of patch to capsule in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) change from baseline to 24 week. Secondary endpoints included cognition (MMSE), overall clinical response (Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change [ADCS-CGIC]), activities of daily living (Alzheimer's Disease Cooperative Study-Activities of Daily Living [ADCS-ADL]), behavior (Neuropsychiatric Inventory [NPI-12]), and safety. RESULTS:Similar cognitive improvement was observed in both patch (n = 248) and capsule (n = 253) groups. Statistical noninferiority for ADAS-Cog was not established (least-square means difference, 0.1; 95% confidence interval, -1.2; 1.5). Considering all efficacy parameters into account, both treatments showed similar performance at Week 24. Treatment-related adverse events (AEs) were lower for patch (39.7%) compared with capsule (49.8%). Application site pruritus was reported in 10.9% of patients receiving patch; most cases were mild. Gastrointestinal AEs including nausea, vomiting, and diarrhea occurred less frequently in the patch group (15.8% vs. 28.7%). CONCLUSION:Rivastigmine patch 9.5 mg/24 h is effective and well tolerated in Chinese patients with probable AD.

SUBMITTER: Zhang ZX 

PROVIDER: S-EPMC6492844 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).

Zhang Zhen-Xin ZX   Hong Zhen Z   Wang Yan-Ping YP   He Li L   Wang Ning N   Zhao Zhong-Xin ZX   Zhao Gang G   Shang Lan L   Weisskopf Marianne M   Callegari Francesca F   Strohmaier Christine C  

CNS neuroscience & therapeutics 20160325 6


<h4>Aims</h4>To compare the once-daily rivastigmine patch 9.5 mg/24 h (10 cm(2) ) versus twice-daily capsule (12 mg/day) in Chinese patients with probable Alzheimer's disease (AD) (mini-mental state examination [MMSE] scores of 10-20).<h4>Methods</h4>The primary objective was to demonstrate the noninferiority of patch to capsule in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) change from baseline to 24 week. Secondary endpoints included cognition (MMSE), overall clinical re  ...[more]

Similar Datasets

| S-EPMC4353453 | biostudies-literature
| S-EPMC4233957 | biostudies-literature
| S-EPMC4607239 | biostudies-literature
| S-EPMC10852722 | biostudies-literature
| S-EPMC10852739 | biostudies-literature
| S-EPMC6495641 | biostudies-literature
| S-EPMC6075877 | biostudies-literature
| S-EPMC3199883 | biostudies-literature
| S-EPMC3025991 | biostudies-literature
| S-EPMC5986675 | biostudies-literature